# Sermorelin Dosage in the Research Literature (Studied Doses Only) > Sermorelin dosage as studied, not prescribed: ~30 mcg/kg/day in the pediatric trial, 0.5-1 mg twice daily in older-men research, IV diagnostic doses, routes, half-life, and stability. What was administered, to which population, by which route — in strict research framing. Nothing here is a dose to take. ## Read this first Everything below is a study dose — what researchers gave, to whom, by what route — not a recommendation. The numbers span a wide range because the populations did: micrograms per kilogram in children, half-milligram and milligram doses in older men, tiny intravenous doses in pharmacokinetic tests. 'mcg' means microgram (a thousandth of a milligram); 'subcutaneous' means injected under the skin; 'IV' means into a vein. This page reports sermorelin dosage as the literature recorded it, and stops there. ## Sermorelin dosage in the research literature Across the published work, sermorelin dosage was studied in clearly separated regimens by population and purpose: - **Pediatric GH-deficiency efficacy:** 30 mcg/kg/day subcutaneous at bedtime, in the multicenter trial that accelerated linear growth in GH-deficient children [1]. - **Aging research in older men:** 0.5 mg and 1 mg subcutaneous twice daily for fourteen days, where the response was dose-related and the 1 mg dose produced the larger GH/IGF-1 effect [2]. - **Pharmacokinetic / diagnostic:** intravenous doses of 0.25-2 mcg/kg elicited GH release in healthy men, with maximal release at 1-2 mcg/kg [3]; a single intravenous bolus (commonly around 1 mcg/kg) was historically used as a GHRH stimulation test of pituitary GH reserve. These are study doses tied to study populations. The digest reports them in 'studied at X in this population' form and makes no claim about what is appropriate for any individual. ## Doses studied: from micrograms to milligrams Research doses span a wide range by population: about 30 mcg/kg/day subcutaneous in the pediatric GH-deficiency trial [1], and 0.5 mg versus 1 mg twice daily in aging research, where the 1 mg dose produced the larger GH/IGF-1 response [2]. These are study doses, not a recommendation, and the right comparison is by population, not by a single number. ## Routes studied Three routes appear in the literature, with very different efficiency. Subcutaneous injection is the primary route used in the efficacy and aging studies [1][2]. Intravenous dosing appears in the diagnostic and pharmacokinetic work [3]. Intranasal administration was tested historically but is inefficient — bioavailability was only about 3-5% [3]. That low mucosal absorption is the research basis for a common caution: oral, sublingual, and troche 'sermorelin' formulations are widely criticized in research-user communities as poorly absorbed, because peptides are degraded in the gut and cross mucosa poorly — consistent with the ~3-5% intranasal figure [3]. ## Sermorelin half-life and pharmacokinetics Sermorelin half-life is short — on the order of ten to twelve minutes in plasma after intravenous administration — and the peptide is rapidly eliminated, yet a single dose elevates serum GH for roughly three hours [3]. The mismatch between a minutes-long half-life and an hours-long GH effect is a recurring feature of the data: a brief pituitary stimulus produces a sustained downstream release. The native peptide's brevity is also what motivated the longer-acting analogs (D-Ala2 substitution and the DAC technology behind CJC-1295), the subject of [sermorelin vs CJC-1295](/vs-cjc-1295). ## Study durations: days to months Trial durations varied widely. Aging-research dosing ran fourteen days for the GH/IGF-1 endpoints [2]; the GHRH-analog cognition trial ran twenty weeks [6]; and the pediatric growth study reported first-year height-velocity outcomes over a year [1]. There is no established adult duration to recommend, and the digest does not propose one. ## Is 3 months of sermorelin enough? Trial durations varied widely: aging-research dosing ran 14 days for GH/IGF-1 endpoints [2], while the pediatric growth and cognition trials ran a year and twenty weeks respectively [1][6]. There is no established adult duration to recommend — 'enough' depends on an endpoint the adult anti-aging literature has not settled. ## Is 500mcg daily sermorelin adequate, or should the dose be 1mg? Research doses span a wide range by population: about 30 mcg/kg/day subcutaneous in the pediatric GH-deficiency trial [1], and 0.5 mg versus 1 mg twice daily in aging research, where the 1 mg dose produced the larger GH/IGF-1 response [2]. These are study doses, not a recommendation, and the comparison the question implies was studied in older men, not generalized. ## Handling and stability, as described Lyophilized (freeze-dried) sermorelin acetate is reconstituted with sterile diluent and, once reconstituted, is typically refrigerated. Aqueous peptide solutions are susceptible to degradation, which is why GHRH(1-29) is supplied as a lyophilized powder rather than a ready solution. Compounded preparations are prepared under USP <797> sterile-compounding standards. These are handling characteristics drawn from the research and compounding literature, recorded here as context — not as preparation instructions. --- A stippled reading of the sermorelin record — each GH and IGF-1 figure dotted back to the study that measured it, the formerly-approved-now-compounded history set straight, and the bare plate where the adult anti-aging data thin left honestly unworked; no clinic behind the plate and nothing here dosed, dispensed, or sold.